Carrillo-Esper R; González-Avila D; Uribe-Ríos M; Méndez-Sánchez N

Idioma: Español
Referencias bibliográficas: 18
Paginas: 87-90
Archivo PDF: 226.18 Kb.

FRAGMENTO

Sin resumen

REFERENCIAS (EN ESTE ARTÍCULO)

1. Strader DB, Wright T, Thomas DL, Seeff LB. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147-71.

2. Chen YC, Lu S-N, Lin M-C. Interstitial pneumonitis after combination therapy with pegylated interferon a-2b and ribavirin for chronic hepatitis C. Chang Gung Med J 2007; 30: 92-7.

3. Tahan V, Ozseker F, Guneylioglu D, Baran A, Ozaras R, Mert A, Ucisik AC, et al. Sarcoidosis after use of interferon for chronic hepatitis C: report of a case and review of the literature. Dig Dis Sci 2003; 48: 169-73.

4. Kumar KS, Russo MW, Borczuk AC, Brown M, Esposito SP, Lobritto SJ, Jacobson IM, et al. Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C. Am J Gastroenterol 2002; 97: 2432-40.

5. Hizawa N, Kojima J, Kojima T, Sukoh N, Yamaguchi E, Kawakami Y, Matsushima T. A patient with chronic hepatitis C who simultaneously developed interstitial pneumonia, hemolytic anemia and cholestatic liver dysfunction after alpha-interferon administration. Intern Med 1994; 33: 337-41.

6. Rönnblom LE, Alm GV, Oberg KE. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med 1991; 115: 178-83.

7. Midturi J, Sierra-Hoffman M, Hurley D, Winn R, Beissner R, Carpenter J. Spectrum of pulmonary toxicity associated with the use of interferon therapy for hepatitis C: Case report and review of the literature. Clin Infect Dis 2004; 39: 1724-9.

8. Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, et al. Pegylated interferon-a2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther 2000; 68: 556-67.

9. Kowdley KV. Hematological side effects of interferon and ribavirin therapy. J Clin Gastroenterol 2005; 39 Suppl 1: S3-S8.

10. Benítez C, Andresen M, Farías G, Castillo C, Henríquez M, Pereira J. Indications, adverse effects and results of plasmapheresis in critical care patients. Rev Med Chil 2005; 133: 1441-8.

11. Lang ZW, Shen B, Zhang L, Shi XH, Ma PQ, Lan MD, Ma ZC, et al. Detection of CD4+CD25+ regulatory T cells in liver tissues of fibrosing cholestatic hepatitis after liver and kidney transplantation. Zhonghua Gan Zang Bing Za Zhi 2007; 15: 667-71.

12. Kojima H, Abei M, Takei N, Mukai Y, Hasegawa Y, Iijima T, Nagasawa T. Fatal reactivation of hepatitis B virus following cytotoxic chemotherapy for acute myelogenous leukemia: fibrosing cholestatic hepatitis. Eur J Hematol 2002; 69: 101-4.

13. Izquierdo MT, Almenar L, Zorio E, Martinez-Dolz L. Viral hepatitis C-related fibrosing cholestatic hepatitis after cardiac transplantation. Med Clin (Barc) 2007; 129: 117-8.

14. Hooda AK, Puri P, Narula AS, Raychaudhury N, Varghese SJ, Basu A. Hepatitis C virus-related fibrosing cholestatic hepatitis in a renal transplant recipient. Indian J Gastroenterol 2006; 25: 308-9.

15. Chen JW, Chen DZ, Chen ZM. Unique pattern of fibrosing cholestatic hepatitis after liver transplantation. Hepatobiliary Pancreat Dis Int 2002; 1: 33-4.

16. Saleh F, Ko HH, Davis JE, Apiratpracha W, Powell JJ, Erb SR, Yoshida EM. Fatal hepatitis C associated fibrosing cholestatic hepatitis as a complication of cyclophosphamide and corticosteroid treatment of active glomerulonephritis. Ann Hepatol 2007; 6: 186-9.

17. Abi-Nassif S, Mark EJ, Fogel RB, Hallisey RK Jr. Pegylated interferon and ribavirin-induced interstitial pneumonitis with ARDS. Chest 2003; 124: 406-10.

18. Chin K, Tabata C, Sataka N, Nagai S, Moriyasu F, Kuno K. Pneumonitis associated with natural and recombinant interferon alfa therapy for chronic hepatitis C. Chest 1994; 105: 939-41.